Quantitative relationship between guanine O6-alkyl lesions produced by Onrigin™ and tumor resistance by O6-alkylguanine-DNA alkyltransferase

Biochemical Pharmacology

Volumn 80, Issue 9, 2010, Pages 1317-1325

  Ishiguro, Kimiko ^a   Zhu, Yong Lian ^a   Shyam, Krishnamurthy ^a   Penketh, Philip G ^a   Baumann, Raymond P ^a   Sartorelli, Alan C ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

101M); Carmustine (BCNU); Cloretazine; Guanine O6 chloroethyl and O6 methyl lesions; O6 Alkylguanine DNA alkyltransferase (AGT); O6 Benzylguanine; Onrigin (laromustine; Temozolomide; VNP40101M

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O CHLOROETHYLGUANINE; 6 O METHYLGUANINE; CARMUSTINE; CLORETAZINE; GUANINE DERIVATIVE; ONRIGIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; GUANINE; HYDRAZINE DERIVATIVE; LAROMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; O-(6)-METHYLGUANINE; SULFONAMIDE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CYTOTOXICITY; DRUG ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR RESISTANCE; ANALOGS AND DERIVATIVES; ANIMAL; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG RESISTANCE; MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARMUSTINE; CELL LINE, TUMOR; DACARBAZINE; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GUANINE; HUMANS; HYDRAZINES; MICE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SULFONAMIDES;

EID: 77956652627     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.022     Document Type: Article

References (41)

1. Shyam K., Penketh P.G., Loomis R.H., Rose W.C., Sartorelli A.C. Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J Med Chem 1996, 39:796-801.
2. Shyam K., Penketh P.G., Divo A.A., Loomis R.H., Patton C.L., Sartorelli A.C. Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J Med Chem 1990, 33:2259-2264.
3. Penketh P.G., Shyam K., Sartorelli A.C. Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol 2000, 59:283-291.
4. Finch R.A., Shyam K., Penketh P.G., Sartorelli A.C. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 2001, 61:3033-3038.
5. Colvin M., Chabner B.A. Alkylating agents. Cancer chemotherapy: principles and practice 1990, 276-313. J.B. Lippincott Company, Philadelphia. B.A. Chabner, J.M. Collins (Eds.).
6. Giles F.J. Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML. Leuk Lymphoma 2007, 48:1064-1066.
7. Giles F., Rizzieri D., Karp J., Vey N., Ravandi F., Faderl S., et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007, 25:25-31.
8. Giles F.J. Laromustine: the return of alkylators to non-myeloablative therapy of AML. Leuk Res 2009, 33:1022-1023.
9. Vey N., Giles F. Laromustine (cloretazine). Expert Opin Pharmacother 2010, 11:657-667.
10. Baumann R.P., Seow H.A., Shyam K., Penketh P.G., Sartorelli A.C. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res 2005, 15:313-325.
11. 6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine. Mol Cancer Ther 2005, 4:1755-1763.
12. Ishiguro K., Seow H.A., Penketh P.G., Shyam K., Sartorelli A.C. Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther 2006, 5:969-976. PMC2680221.
13. Ludlum D.B. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest 1997, 15:588-598.
14. 6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol 2004, 53:279-287.
15. 6-alkylguanine by alkyltransferases. Mutat Res 2000, 462:83-100.
16. 6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair (Amst) 2007, 6:1100-1115.
17. 6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother Pharmacol 2004, 53:288-295.
18. Rice K.P., Penketh P.G., Shyam K., Sartorelli A.C. Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU. Biochem Pharmacol 2005, 69:1463-1472.
19. Gerson S.L. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002, 20:2388-2399.
20. 6-Alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 2002, 24:255-266.
21. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 1990, 87:5368-5372.
22. 6-alkylguanine-DNA alkyltransferase. J Med Chem 1992, 35:4486-4491.
23. Shyam K., Hrubiec R.T., Furubayashi R., Cosby L.A., Sartorelli A.C. 1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity. J Med Chem 1987, 30:2157-2161.
24. 6-benzylguanine to the protein. Anal Biochem 2008, 383:44-51. PMC2773450.
25. Penketh P.G., Shyam K., Sartorelli A.C. Studies on the mechanism of decomposition and structural factors affecting the aqueous stability of 1,2-bis(sulfonyl)-1-alkylhydrazines. J Med Chem 1994, 37:2912-2917.
26. Wiencke J.K., Wiemels J. Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Mutat Res 1995, 339:91-119.
27. 3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987, 47:5846-5852.
28. Koay D.C., Sartorelli A.C. Functional differentiation signals mediated by distinct regions of the cytoplasmic domain of the granulocyte colony-stimulating factor receptor. Blood 1999, 93:3774-3784.
29. Bartsch W., Sponer G., Dietmann K., Fuchs G. Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20. Arzneimittelforschung 1976, 26:1581-1583.
30. Brent T.P., Dolan M.E., Fraenkel-Conrat H., Hall J., Karran P., Laval L., et al. Repair of O-alkylpyrimidines in mammalian cells: a present consensus. Proc Natl Acad Sci USA 1988, 85:1759-1762.
31. 4-methylthymine repair by eukaryotic methyltransferases. J Biol Chem 1991, 266:2767-2771.
32. 6 position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents. Cancer Invest 1984, 2:223-231.
33. 6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 1991, 12:1857-1867.
34. 6-methylguanine residues in genomic DNA and production of sister-chromatid exchanges, mutations and lethal events in a Mer- human tumor cell line. Mutat Res 1994, 314:99-113.
35. 6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides. Nucleic Acids Res 1988, 16:6779-6788.
36. 6-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2001, 7:2309-2317.
37. Gururangan S., Turner C.D., Stewart C.F., O'Shaughnessy M., Kocak M., Poussaint T.Y., et al. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res 2008, 14:1124-1130.
38. Lown J.W., Chauhan S.M. Mechanism of action of (2-haloethyl)nitrosoureas on DNA. Isolation and reactions of postulated 2-(alkylimino)-3-nitrosooxazolidine intermediates in the decomposition of 1,3-bis(2-chloroethyl)-, 1-(2-chloroethyl)-3-cyclohexyl-, and 1-(2-chloroethyl)-3-(4'-trans-methylcyclohexyl)-1-nitrosourea. J Med Chem 1981, 24:270-279.
39. Tong W.P., Kohn K.W., Ludlum D.B. Modifications of DNA by different haloethylnitrosoureas. Cancer Res 1982, 42:4460-4464.
40. Liu L., Yan L., Donze J.R., Gerson S.L. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol Cancer Ther 2003, 2:1061-1066.
41. Tentori L., Graziani G. Recent approaches to improve the antitumor efficacy of temozolomide. Curr Med Chem 2009, 16:245-257.